The short version of Proline-rich sequence fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-04 and is reviewed periodically as new material appears.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
Oral fluphenazine rapidly absorbs and plasma levels peak at about 1.0-2.5 ng/mL 2 hours post-ingestion. The volume of distribution is about 298 L due to extensive tissue uptake, and it crosses the blood brain barrier. Bioavailability is low at 2.7% due to first pass metabolism, and the half-life is about 14–16 hours. Steady state concentrations vary considerably across individuals, which indicates variability in absorption, metabolism, or excretion. Additionally, the dose-level relationship is curvilinear with plasma levels of 0.2 - 2.8 ng/mL being optimal for clinical improvement. Fluphenazine is primarily metabolized to fluphenazine sulfoxide by the cytochrome P450 2D6. Benztropine mesylate did not indicate any major drug-drug interactions. Fluphenazine is exreted primarily through urine and feces. Injectable fluphenazine is dissolved in sesame oil which forms a localized oil depot in the muscle. Due to the lipophilicity of the added decanoate or enanthate group, the drug remains in the oil causing the rate-limiting step for drug being diffusion out, resulting in flip-flop kinetics. Fluphenazine decanoate and enanthate are prodrugs which are hydrolyzed by esterases to fluphenazine. The fluphenazine decanoate acts within 1–3 days, and its effect lasts an average of 2 weeks. The half-life of fluphenazine decanoate is about 6.8-9.6 days, and plasma levels peak at about 2.18 ng/mL about 4–6 hours post injection. Fluphenazine enanthate has a lower half life of about 3.6-3.7 days, reflecting its decreased lipophilicity.
=== Co-morbidities === BED often happens with diabetes, stroke, and heart disease. People who experience OCD or bipolar disorder have a greater chance of dealing with BED. Additionally, 30 to 40 percent of individuals seeking treatment for weight loss can be diagnosed with binge eating disorder.
== Additional reading == Zelzer, M. (2015), "Peptide-based switchable and responsive surfaces", Switchable and Responsive Surfaces and Materials for Biomedical Applications, Elsevier, pp. 65–92, doi:10.1016/b978-0-85709-713-2.00003-1, ISBN 978-0-85709-713-2, retrieved 2023-04-30 Schwartz, Jeffrey; Avaltroni, Michael J; Danahy, Michael P; Silverman, Brett M; Hanson, Eric L; Schwarzbauer, Jean E; Midwood, Kim S; Gawalt, Ellen S (2003). "Cell Attachment and Spreading on Metal Implant Materials". Materials Science and Engineering: C. 23 (3): 395–400. doi:10.1016/S0928-4931(02)00310-7.
Sources: en.wikipedia.org
Soft tofu, also known as "silken tofu", is called nèndòufu (嫩豆腐; "soft tofu") or huádòufu (滑豆腐, "smooth tofu") in Chinese; kinugoshi-dōfu (絹漉し豆腐; "silk-filtered tofu") in Japanese; and yeon-dubu (Korean: 연두부; Hanja: 軟豆腐; "soft tofu") in Korean. Gelled with gypsum, this tofu is undrained, and unpressed, and contains a high moisture content. Silken tofu is produced by coagulating soy milk without cutting the curd. Silken tofu is available in several consistencies, including soft and firm, but all silken tofu is more delicate than regular firm tofu (pressed tofu) and it has different culinary uses. Silken tofu can be used as a substitute for dairy products and eggs, especially for smoothies and baked desserts. Douhua (豆花, also known as 豆腐花, dòufuhuā in Chinese), or tofu brain (豆腐腦 or 豆腐脑, dòufunǎo in Chinese) or dau fa (Cantonese) and tau hua (Fujianese) (豆花; "bean flower") is similar to silken tofu, but is typically served a few hours after it is prepared. It is most often eaten as a hot dessert, but sometimes salty pickles or hot sauce are added. This is a type of soft tofu with very high moisture content. Because using chopsticks make douhua difficult to pick up, it is generally eaten with a spoon. With the addition of flavorings such as finely chopped green onions, dried shrimp, soy sauce, or chilli sauce, douhua is a popular breakfast dish across China. In Malaysia, douhua is usually served warm with white or dark palm sugar syrup, or served cold with longans. It is frequently served at breakfast or for dessert.
The paper used for fuel filters is a crêped paper with controlled porosity, which is pleated and wound to cartridges. The raw material for filter paper used in fuel filters are made of a mixture of hardwood and softwood fibres. The basis weight of the paper is 50–80 g/m2.
== Historical use == Spirulina was a food source for the Aztecs and other Mesoamericans until the 16th century; the harvest from Lake Texcoco in Mexico and subsequent sale as cakes were described by one of Cortés' soldiers. The Aztecs called it tecuitlatl. Spirulina was found in abundance at Lake Texcoco by French researchers in the 1960s, but no reference to its use by the Aztecs as a daily food source was made after the 16th century, probably because of the draining of the surrounding lakes for agriculture and urban development. The topic of tecuitlatl, which was discovered in 1520, was not mentioned again until 1940, when the Belgian phycologist Pierre Dangeard mentioned a cake called dihe consumed by the Kanembu people, who harvest it from Lake Chad in the African nation of Chad. Dangeard studied the dihe samples and found it to be a dried purée of the spring form of the blue-green algae from the lake. The dihe is used to make broths for meals, and also sold in markets. The spirulina is harvested from small lakes and ponds around Lake Chad. During 1964 and 1965, the botanist Jean Leonard confirmed that dihe is made up of spirulina, and later studied a bloom of algae in a sodium hydroxide production facility. As a result, the first systematic and detailed study of the growth requirements and physiology of spirulina was performed as a basis for establishing large-scale production in the 1970s.
=== February–April 1881 === On 14 February Carrington captured Ramokoatsi, which overlooked the main road to Morija. The following day, a force of 370 cavalry, 100 infantry, 50 native levies, and three artillery pieces under Brabant was sent out in search of a new camping ground. Upon crossing a spruit in the Ramibidikwa area, a CMR scout reported a massed formation of Basuto horsemen. Brabant ordered his soldiers to form a square; soon afterwards the Basuto commenced an attack on its front and two flanks. A combination of rifle and case shot fire kept the Basuto at bay in the center and the right flank. On the left, the Basuto managed to almost reach melee range before being likewise driven off. The artillery continued to fire on the retreating Basuto, who suffered 138 casualties in the engagement. One month later Clarke assumed personal command of the force, moving the camp to Ramibidikwa, 20 miles (32 km) from Morija. On 22 March, Carrington was heavily wounded in the vicinity of the new camp. By early April, Sprigg's conduct of the war was being heavily criticized in the Cape Parliament, whose opposition members were pushing for a vote of no confidence. Using Letsie as an intermediary, Robinson organized a meeting between Griffith and Lerotholi outside Maseru on 17 April. The two sides signed an armistice, although Lerotholi was unwilling to surrender his weapons, as the motion would be too unpopular among his tribesmen. On 29 April, Robinson announced the peace settlement, known as the Award.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.